The cornerstone of Evotec’s in vitro biology function is disease and target biology expertise coupled with state-of-the-art technology platforms. A large team of ~400 scientists with extensive industrial experience supports the in vitro pharmacological characterisation of compounds as part of hit expansion, lead finding and lead optimisation projects, generating project-relevant high-quality data in short turnaround times. In addition, biomarker discovery and development is integrated into every project, ensuring the co-development of pharmacodynamic, as well as patient stratification and toxicology biomarkers. Target validation, complex cellular screening, mechanism of action studies and early translational biology research complete the breadth of activities performed by the Evotec team in eukaryotic and prokaryotic systems.
Evotec’s core expertise covers therapeutic areas such as CNS diseases, pain, inflammation & immunology, fibrosis, metabolic diseases, oncology and anti-infectives, and extends into a variety of rare diseases. The therapeutic area expertise is combined with in-depth know-how in relevant target classes, including classical target families such as GPCRs, ion channels and kinases, as well as a large diversity of other target areas such as transporters, protein-protein interactions and multiple enzyme families. Building upon a modality-agnostic platform, the scientific team is also familiar with not only small molecule drug development, but also various biologic, gene therapy and cell therapy approaches. With access to a world-class portfolio of assay technologies for biochemical and cellular assays, our drug discovery and disease biology expertise has been repeatedly proven to be a driver of success for our partner’s projects.
